Ambroxol powered by LipodisqTM Sterile Solution Cat. No. #IAX-700-108

Nano-formulated aqueous Ambroxol (sterile) solution: Ready-to-use!

  • Ambroxol is a mucolytic agent used in the treatment of respiratory diseases. Ambroxol is
    a basic (pKa = 9.01) cationic drug with lipophilic properties (logP = 2.9), enabling it to act as
    a lysosomotropic agent. In addition, ambroxol exhibits a novel mechanism by accumulating in
    lamellar bodies and acting as a lysosomal secretagogue.
    • A wide range of pharmacological effects of ambroxol have been confirmed, including mucus
    regulation, anti-inflammatory, reduction of arachidonic acid metabolites and pro-inflammatory
    cytokines, and antioxidant properties. In addition, ambroxol aids in the enhancement of local
    defence molecules involved in respiratory viral replication.
    • Ambroxol is a sodium channel blocker and mucolytic agent with antioxidant, anti-viral and antiinflammatory
    properties. Inhibits tetrodotoxin (TTX)-resistant channels more potently than
    TTX-sensitive subtypes. Inhibits release of histamine, leukotrienes and cytokines from human
    leukocytes and mast cells. Inhibits viral replication and improves survival rate of mice infected
    with influenza (H3N2) virus. It is a candidate for use as an anti-COVID19 therapeutic.
£185.00

Choose your options

Synonyms: Trans-4-[[(2-amino-3,5-dibromophenyl)methyl]amino]cyclohexan-1-ol hydrochloride]
in a detergent-free nano-formulation made of styrene-maleic acid lipid particles (SMALP)

Empirical Formula: C13H18Br2N2O . HCL


Concentration: 1mg/ml / 0.1% (w/vol) Ambroxol in LipodisqTM


Size: 1ml


MW: 414.56 . 36.5


CAS: 23828-92-4


Purity: ≥95% (HPLC)


Solubility:
Soluble in water, PBS, Tris and other physiological solutions as formulated in a proprietary, thermostable, aqueous lipid nanoparticulate formulation (LipodisqTM, Malvern Cosmeceutics Ltd., Malvern UK).

Avoid the use of buffers with divalent ions such as Ca or Mg or pH <6.5 or >8.0, which can cause particle instability.

Unformulated Ambroxol is soluble inDMF, DMSO or ethanol and is poorly soluble in aqueous solutions.


Formulation:
LipodisqTM are nanosized lipid-based discoidal particles that can be manufactured to incorporate hydrophobic, poorly water-soluble compounds, such as lipids, lipoproteins and glycolipids.


Appearance: Colourless clear aqueous solution


Handling: Keep sterile. Avoid skin and eye contact.


Activity:

  • Cell culture tested (human macrophage cell line) (MTT).
  • Recommended starting dilution: 1:200 or higher.
  • Optimal working concentrations depend on the applications and need to be determined.
  • Published procedures using LipodisqTM formulations (Curcumin and IAXO TLR4 antagonists) in vivo rodent models at 3-10mg/kg.
  • Recommended route of administration is subcutaneous (s.c.) with oral or nasal application as a possible alternative, which needs to be optimised.
  • Carrier only control: LipodisqTM Control Sterile Solution (Cat. No.: IAX-700-100).

Shipping: Ambient


Storage: 2-8°C


Stability: 12 months after receipt (unopened and as supplied)


LipodisqTM Technology
  • A nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilised by a chaperone molecule annulus.
  • Internal properties of the phospholipid membrane support the disposition and stabilisation of drug molecule candidates and preserve the native conformation of membrane molecules.
  • The resulting encapsulated actives are rendered water-soluble and specialised for intra-cellular penetration/delivery via endosomal uptake mechanisms.
  • LipodisqTM solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
  • For a customizable biodegradable LipodisqTM version with a higher concentration of actives or an alternative lipid option, contact Innaxon.

Innaxon as the supplier also welcomes BULK enquiries for this product.

LipodisqTM References:

[1] Mechanisms of Formation, Structure, and Dynamics of Lipoprotein Discs Stabilized by Amphiphilic Copolymers: A Comprehensive Review. Orekhov PS, et al. Nanomaterials (2022); 12:361
[2] Applications of Synthetic Polymer Discoidal Lipid Nanoparticles to Biomedical Research. Tanaka M. Chem. Pharm. Bull. (2022); 70:507
[3] Understanding the Structural Pathways for Lipid Nanodisc Formation: How Styrene Maleic Acid Copolymers Induce Membrane Fracture and Disc Formation. Bjørnestad VA, et al. Langmuir (2021);37:6178
[4] Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin.Torgersen ML, et al.J.     Biomed.Nanotechnol. (2020); 16:4
[5] Effects of charged lipids on the physicochemical and biological properties of lipid–styrene maleic acid copolymer discoidal particles. Tanakaa M, et al. Biochim. Biophys. Acta. Biomembr. (2020); 1862:183209
[6] From polymer chemistry to structural biology: The development of SMA and related amphipathic polymers for membrane protein extraction and solubilization. Bada Juarez JF, et al. Chem. Phys. Lipids. (2019);  221:167
[7] The styrene–maleic acid copolymer: a versatile tool in membrane research. Dörr JM, et al. Eur. Biophys. J. (2016); 45:3
[8] Reconstitution of membrane proteins: a GPCR as an example. Goddard AD, et al. Methods Enzymol. (2015); 556:405
[9] Nano-size uni-lamellar lipodisq improved in situ auto-phosphorylation analysis of E. coli tyrosine kinase using (19)F nuclear magnetic resonance. Li D, et al. Protein Cell (2015); 6:229
[10] Characterizing the structure of lipodisq nanoparticles for membrane protein spectroscopic studies. Zhang R, et al. Biochim. Biophys. Acta. (2015); 1848:329
[11] Advances in the use of nanoscale bilayers to study membrane protein structure and function. Malhotra K and Alder NN. Biotechnol. Genet. Eng. Rev. (2014); 30:79
[12] DEER EPR measurements for membrane protein structures via bifunctional spin labels and lipodisq nanoparticles. Sahu ID, et al. Biochemistry (2013); 52:6627
[13] Detergent-free formation and physicochemical characterization of nanosized lipidpolymer complexes: Lipodisq. Orwick MC, et al. Angew. Chem. (2012); 51:4653
[14] Detergent-free incorporation of a seven-transmembrane receptor protein into nanosized bilayer lipodisq particles for functional and biophysical studies. Orwick-Rydmark M, et al. Nano Lett. (2012); 12:4687
[15] In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles:survival improvement and inhibition of liver metastases. Daruwalla, J, et al. Cancer Sci. (2010); 101:1866
[16] Poly(styrene-alt-maleic anhydride) derivatives as potent anti-HIV microbicide candidates. Fang W, et al. Bioorg. Med. Chem. Lett. (2009); 19:1903
[17] SMA–doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. Greish K, et al. J. Control. Release (2004); 97:219
[18] Responsive Hydrophobically Associating Polymers: A Review of Structure and Properties.Tonge, SR and Tighe, BJ. Adv. Drug Deliv. Rev. (2001): 53:109


General Ambroxol Information

  • Ambroxol is a mucolytic agent used in the treatment of respiratory diseases. Ambroxol is a basic (pKa = 9.01) cationic drug with lipophilic properties (logP = 2.9), enabling it to act as a lysosomotropic agent. In addition, ambroxol exhibits a novel mechanism by accumulating in lamellar bodies and acting as a lysosomal secretagogue.
  • A wide range of pharmacological effects of ambroxol have been confirmed, including mucus regulation, anti-inflammatory, reduction of arachidonic acid metabolites and pro-inflammatory cytokines, and antioxidant properties. In addition, ambroxol aids in the enhancement of local defence molecules involved in respiratory viral replication.
  • Ambroxol is a sodium channel blocker and mucolytic agent with antioxidant, anti-viral and antiinflammatory properties. Inhibits tetrodotoxin (TTX)-resistant channels more potently than TTX-sensitive subtypes. Inhibits release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inhibits viral replication and improves survival rate of mice infected with influenza (H3N2) virus.
  • It is a candidate for use as an anti-COVID19 therapeutic.

Ambroxol Literature References
[1] Ambroxol in the 21st century: pharmacological and clinical update. Malerba M, Ragnoli B. Expert Opin.
Drug. Metab. Toxicol. (2008); 4:1119 Review
[2] Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a singlecentre,
randomized, double-blind, placebo-controlled trial. Silveira, CRA, et al. BMC Neurol. (2019);
19:20
[3] Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic
Pain-Narrative. Kocot-Kępska M, et a. Pharmaceutics (2021); 13:450 Review
[4] Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells.
Carpinteiro A, et al. J. Biol. Chem. (2021); 296: 100701
[5] Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2. Alkotaji M. Int. J.
Antimicrob. Agents (2020); 56: 106192


Legal Claim
The LipodisqTM technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending.

The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.


Authorized Uses & Restrictions
The purchase of Innaxon product(s) conveys to the buyer the non-transferable right to use the purchased amount of the product and all replicates and derivatives for, internal, non-profit research purposes. The buyer cannot sell, resale or otherwise transfer (a) the product (b) its components or (c) materials made using this product or its components to a third party. The buyer agrees that any activity undertaken with the product and replicates or derivatives will be conducted in compliance with all applicable guidelines, aws, and regulations. The buyer agrees that the product and replicates or derivatives will not be used for any animal or human therapeutic or diagnostic use.


Limited Use License
Purchase does not include any other right or license to use, develop or otherwise exploit our products. Any use of Innaxon products outside of the Authorized Uses requires additional rights from the Licensor.


Download Product Resources

Flyers
Product Data Sheets
Safety Data Sheets

Code IAX-700-108-L001

Product Data Sheets

 IAX-100-001 Lipid A from S. minnesota R595 (Re) TLRpureTM Sterile Solution
 IAX-100-002 MPLA from S. minnesota R595 (Re) TLRpureTM Sterile Solution
 IAX-100-003 MPLA from E coli R515 (Re) TLRpureTM Sterile Solution
 IAX-100-004 Lipid A from E. coli R515 (Re) TLRpureTM Sterlie Solution

 IAX-100-006 LPS from E. coli O8:K27 (S-form) TLRpureTM Sterile Solution
 IAX-100-007 LPS from E. coli R515 (Re) Sterile Solution 
 IAX-100-008 LPS from S. minnesota R595 (Re) TLRpureTM Sterile Solution
 IAX-100-009 LPS (Universal) from S. abortus equi (S-form) TLRpureTM Sterile Solution
 IAX-100-009B LPS from S. abortus equi (S-form) Biotin TLRpureTM Sterile Solution
 IAX-100-010 LPS from E. coli EH100 (Ra) TLRpureTM Sterile Solution
 IAX-100-011 LPS from S. typhimurium (S-form) TLRpureTM Sterile Solution
 IAX-100-012 LPS from E. coli O111:B4 (S-form) TLRpureTM Sterile Solution
 IAX-100-013 LPS from E. coli O55:B5 (S-form) TLRpureTM Sterile Solution
 IAX-100-014 LPS from E. coli J5 (Rc) TLRpureTM Sterile Solution
 IAX-100-015 LPS from S. minnesota R345 (Rb) TLRpureTM Sterile Solution
 IAX-100-016 LPS from S. minnesota R60 (Ra) TLRpureTM Sterile Solution
 IAX-100-017 LPS from S. minnesota R5 (Rc) Sterile Solution
 IAX-100-018 LPS from S. minnesota R7 (Rd1) TLRpureTM Sterile Solution
 IAX-100-019 LPS from S. enteritidis (S-form) TLRpureTM Sterile Solution
 IAX-100-020 LPS from S. minnesota (S-form) TLRpureTM Sterile Solution
 IAX-100-021 LPS from S. minnesota R3 (Rd2) Sterile Solution

 IAX-200-001 ODN 1668 (Type B) Endotoxin-free (sterile)
 IAX-200-002 ODN 1826 (Type B) Endotoxin-free (sterile)
 IAX-200-003 ODN 1585 (Type A) Endotoxin-free (sterile)
 IAX-200-004 ODN M362 (Type C) Endotoxin-free (sterile)
 IAX-200-005 ODN 2216 (Type A) Endotoxin-free (sterile)
 IAX-200-006 ODN 2006 (Type B) Endotoxin-free (sterile)
 IAX-200-007 ODN 2395 (Type C) Endotoxin-free (sterile)

 IAX-200-050 iODN 2088 (Class I) Endotoxin-free (sterile)
​​​​​​​ IAX-200-051 iODN (ttaggg)4 (Class II) Endotoxin-free (sterile)
​​​​​​​ IAX-200-052 G-type iODN (Class I) Endotoxin-free (sterile)
​​​​​​​ IAX-200-053 Mini-iODN (Class I) Endotoxin-free (sterile)
​​​​​​​ IAX-200-054 Mega-iODN (Class I/ll) Endotoxin-free (sterile)
​​​​​​​ IAX-200-055 Duo-iODN (Class I) Endotoxin-free (sterile)
​​​​​​​ IAX-200-056 TLR7-iODN (inhibitory ODN) Endotoxin-free (sterile)

​​​​​​​ IAX-200-101 Trehalose 6,6’-dimycolate [Cord Factor] Endotoxin-free (sterile)

​​​​​​​ IAX-200-200 ODN 1720 (Control for ODN 1668) Endotoxin-free (sterile)
​​​​​​​ IAX-200-201 ODN 2138 (Control for ODN 1826) Endotoxin-free (sterile)
​​​​​​​ IAX-200-202 Neutral-ODN (Control for iODNs) Endotoxin-free (sterile)
​​​​​​​ IAX-200-203 ODN 2118 (Control for ODN 1585) Endotoxin-free (sterile)
​​​​​​​ IAX-200-204 ODN M383 (Control for ODN M362) Endotoxin-free (sterile)
​​​​​​​ IAX-200-205 ODN 2243 (Control for ODN 2216) Endotoxin-free (sterile)
​​​​​​​ ​​​​​​​IAX-200-206 ODN 2137 (Control for ODN 2006) Endotoxin-free (sterile)
​​​​​​​ IAX-200-208 CTRL2-ODN (Control for iODN and CpG-ODNs) Endotoxin-free (sterile)

​​​​​​​ IAX-400-002 Anti-TLR4 (Human) mAb (Blocking)
​​​​​​​ IAX-400-003 Anti-TLR4 (Human) mAb (2EII)
​​​​​​​ IAX-400-004-C100 Anti-TLR4 (human) mAb (28H7)

​​​​​​​ IAX-600-001 IAXO-101
​​​​​​​ IAX-600-002 IAXO-102
​​​​​​​ IAX-600-003 IAXO-103
​​​​​​​ IAX-600-004 IAXO-201 (Control for IAXO-102)
​​​​​​​ IAX-600-005 IAXO-202 (Control for IAXO-101 and IAXO-103)

​​​​​​​ IAX-700-001 Argania Spinosa Kernel Oil (natural) (pure)

​​​​​​​ IAX-700-100 Lipodisq Control (sterile)
​​​​​​​ ​​​​​​​IAX-700-101 Nano-Curcumin Lipodisq (sterile)
​​​​​​​ IAX-700-102 Melatonin Lipodisq (sterile)
​​​​​​​ IAX-700-103 Metformin Lipodisq (sterile)
​​​​​​​ IAX-700-104 Oxyresveratrol Lipodisq (sterile)
​​​​​​​ IAX-700-105 Resveratrol Lipodisq (sterile)
​​​​​​​ IAX-700-106 Umifenovir Lipodisq (sterile)
​​​​​​​ IAX-700-107 Dexamethasone Lipodisq
​​​​​​​ IAX-700-108 Ambroxol Lipodisq (sterile)
 
​​​​​​​ IAX-900-001 PBS Endotoxin-free (sterile)
​​​​​​​ IAX-900-002 ddWater Endotoxin-free (sterile)
​​​​​​​ IAX-900-003 Physiological Saline [NaCl 0.9%] Endotoxin-free (sterile)
​​​​​​​ IAX-900-004 PBS with EDTA Endotoxin-free (sterile)
​​​​​​​ IAX-900-005 TRIS with EDTA (TE Buffer) (100x)
​​​​​​​


Safety Data Sheets

​​​​​​​ IAX-100-001 Lipid A from S. minnesota R595 (Re) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-002 MPLA from S. minnesota R595 (Re) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-003 MPLA from E coli R515 (Re) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-004 Lipid A from E. coli R515 (Re) TLRpureTM Sterlie Solution

​​​​​​​ IAX-100-006 LPS from E. coli O8:K27 (S-form) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-007 LPS from E. coli R515 (Re) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-008 LPS from S. minnesota R595 (Re) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-009 LPS (Universal) from S. abortus equi (S-form) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-009B LPS from S. abortus equi (S-form) Biotin TLRpureTM Sterile Solution
​​​​​​​ IAX-100-010 LPS from E. coli EH100 (Ra) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-011 LPS from S. typhimurium (S-form) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-012 LPS from E. coli O111:B4 (S-form) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-013 LPS from E. coli O55:B5 (S-form) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-014 LPS from E. coli J5 (Rc) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-015 LPS from S. minnesota R345 (Rb) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-016 LPS from S. minnesota R60 (Ra) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-017 LPS from S. minnesota R5 (Rc) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-018 LPS from S. minnesota R7 (Rd1) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-019 LPS from S. enteritidis (S-form) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-020 LPS from S. minnesota (S-form) TLRpureTM Sterile Solution
​​​​​​​ IAX-100-021 LPS from S. minnesota R3 (Rd2) TLRpureTM Sterile Solution

​​​​​​​ IAX-200-001 ODN 1668 (Type B) Endotoxin-free (sterile)
​​​​​​​ IAX-200-002 ODN 1826 (Type B) Endotoxin-free (sterile)
​​​​​​​ IAX-200-003 ODN 1585 (Type A) Endotoxin-free (sterile)
​​​​​​​ IAX-200-004 ODN M362 (Type C) Endotoxin-free (sterile)
​​​​​​​ IAX-200-005 ODN 2216 (Type A) Endotoxin-free (sterile)
​​​​​​​ IAX-200-006 ODN 2006 (Type B) Endotoxin-free (sterile)
​​​​​​​ IAX-200-007 ODN 2395 (Type C) Endotoxin-free (sterile)


​​​​​​​ IAX-200-050 iODN 2088 (Class I) Endotoxin-free (sterile)
​​​​​​​ IAX-200-051 iODN (ttaggg)4 (Class II) Endotoxin-free (sterile)
​​​​​​​ IAX-200-052 G-type iODN (Class I) Endotoxin-free (sterile)
​​​​​​​ IAX-200-053 Mini-iODN (Class I) Endotoxin-free (sterile)
​​​​​​​ IAX-200-054 Mega-iODN (Class I/ll) Endotoxin-free (sterile)
​​​​​​​ IAX-200-055 Duo-iODN (Class I) Endotoxin-free (sterile)
​​​​​​​ IAX-200-056 TLR7-iODN (inhibitory ODN) Endotoxin-free (sterile)

​​​​​​​ IAX-200-101 Trehalose 6,6’-dimycolate [Cord Factor] Endotoxin-free (sterile)

​​​​​​​ IAX-200-200 ODN 1720 (Control for ODN 1668) Endotoxin-free (sterile)
​​​​​​​ ​​​​​​​IAX-200-201 ODN 2138 (Control for ODN 1826) Endotoxin-free (sterile)
​​​​​​​ IAX-200-202 Neutral-ODN (Control for iODNs) Endotoxin-free (sterile)
​​​​​​​ IAX-200-203 ODN 2118 (Control for ODN 1585) Endotoxin-free (sterile)
​​​​​​​ IAX-200-204 ODN M383 (Control for ODN M362) Endotoxin-free (sterile)
​​​​​​​ IAX-200-205 ODN 2243 (Control for ODN 2216) Endotoxin-free (sterile)
​​​​​​​ ​​​​​​​IAX-200-206 ODN 2137 (Control for ODN 2006) Endotoxin-free (sterile)
​​​​​​​ IAX-200-208 CTRL2-ODN (Control for iODN and CpG-ODNs) Endotoxin-free (sterile)

​​​​​​​ IAX-600-001 IAXO-101
​​​​​​​ IAX-600-002 IAXO-102
​​​​​​​ IAX-600-003 IAXO-103

​​​​​​​ IAX-700-001 Argania Spinosa Kernel Oil (natural) (pure)

​​​​​​​ IAX-900-001 PBS Endotoxin-free (sterile)
​​​​​​​ IAX-900-002 ddWater Endotoxin-free (sterile)
​​​​​​​ IAX-900-003 Physiological Saline [NaCl 0.9%] Endotoxin-free (sterile)​​​​​​​



Need additional information?
Please get in touch via email: info@innaxon.com